BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain four FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
Current indications include major depressive disorder, obsessive-compulsive disorder, smoking addiction, and anxious depression. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway.
Israel Trade and Economic Commission in Sydney, Australia 